FDA staff struggle to meet product review deadlines after DOGE layoffs

Claims supported by this source

1. factreported

   Reuters reported that FDA staff were struggling to meet drug and medical-device review deadlines after DOGE layoffs removed support and review personnel, creating approval uncertainty for patients and manufacturers.

   Passages and source records documenting: FDA layoffs put drug and device review deadlines at risk

   FDA layoffs put drug and device review deadlines at risk · FDA teams reported difficulty meeting statutory product-review deadlines

2. factreported

   HHS's restructuring plan and subsequent reporting put the FDA reduction at approximately 3,500 positions, including staff supporting reviews, inspections, communications, and contracting.

   Passages and source records documenting: HHS restructuring eliminated about 3,500 FDA positions

   HHS restructuring eliminated about 3,500 FDA positions · HHS announced approximately 3,500 FDA position cuts

3. factreported

   House Oversight Democratic staff, citing agency communications and reporting, found FDA offices soliciting scientists to volunteer for contracting duties after DOGE-era layoffs removed procurement personnel.

   Operational red-tape and FDA examples

   FDA scientists were asked to volunteer for contracting work after procurement layoffs · Agency offices used volunteer workarounds for eliminated contracting capacity